Anna Vilgelm, M.D., Ph.D.

Research Assistant Professor
Faculty Appointments
Research Assistant Professor of Pharmacology
Ph.D., Molecular Biology, Russian Academy of Sciences, Moscow, RussiaM.D., Medicine, Russian State Medical University, Moscow, RussiaM.Sc., Biochemistry, Russian State Medical University, Moscow, Russia
Yang J, Kumar A, Vilgelm AE, Chen SC, Ayers GD, Novitskiy SV, Joyce S, Richmond A. Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Cancer Immunol Res [print-electronic]. 2018 Oct; 6(10): 1186-98. PMID: 30108045, PMCID: PMC6170679, PII: 2326-6066.CIR-18-0045, DOI: 10.1158/2326-6066.CIR-18-0045, ISSN: 2326-6074.

Vilgelm AE, Cobb P, Malikayil K, Flaherty D, Andrew Johnson C, Raman D, Saleh N, Higgins B, Vara BA, Johnston JN, Johnson DB, Kelley MC, Chen SC, Ayers GD, Richmond A. MDM2 Antagonists Counteract Drug-Induced DNA Damage. EBioMedicine [print-electronic]. 2017 Oct; 24: 43-55. PMID: 29030058, PMCID: PMC5652019, PII: S2352-3964(17)30369-9, DOI: 10.1016/j.ebiom.2017.09.016, ISSN: 2352-3964.

Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, Sobolik T, Lavender N, Johnson AC, McClain C, Ayers GD, Kelley MC, Sanders M, Mayer IA, Moses HL, Boothby M, Richmond A. PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses. Clin. Cancer Res [print-electronic]. 2017 Jul 7/1/2017; 23(13): 3371-84. PMID: 28003307, PMCID: PMC5479746, PII: 1078-0432.CCR-16-2142, DOI: 10.1158/1078-0432.CCR-16-2142, ISSN: 1078-0432.

Vilgelm AE, Johnson DB, Richmond A. Combinatorial approach to cancer immunotherapy: strength in numbers. J. Leukoc. Biol [print-electronic]. 2016 Aug; 100(2): 275-90. PMID: 27256570, PII: jlb.5RI0116-013RR, DOI: 10.1189/jlb.5RI0116-013RR, ISSN: 1938-3673.

Vilgelm AE, Johnson CA, Prasad N, Yang J, Chen SC, Ayers GD, Pawlikowski JS, Raman D, Sosman JA, Kelley M, Ecsedy JA, Shyr Y, Levy SE, Richmond A. Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment. J. Natl. Cancer Inst [electronic-print]. 2016 Jun; 108(6): djv406. PMID: 26719346, PMCID: PMC4849355, PII: djv406, DOI: 10.1093/jnci/djv406, ISSN: 1460-2105.

Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016 Jan 1/29/2016; 7: 10582. PMID: 26822383, PMCID: PMC4740184, PII: ncomms10582, DOI: 10.1038/ncomms10582, ISSN: 2041-1723.

Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, Kelley MC, Richmond A. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models. Clin. Cancer Res [print-electronic]. 2015 Dec 12/1/2015; 21(23): 5338-48. PMID: 26152738, PMCID: PMC4668227, PII: 1078-0432.CCR-15-0293, DOI: 10.1158/1078-0432.CCR-15-0293, ISSN: 1078-0432.

Vilgelm A, Richmond A. Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses. Oncoimmunology. 2015 Aug; 4(8): e1009299. PMID: 26405565, PMCID: PMC4570092, PII: 1009299, DOI: 10.1080/2162402X.2015.1009299, ISSN: 2162-4011.

Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart CF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN, Richmond A. Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res [print-electronic]. 2015 Jan 1/1/2015; 75(1): 181-93. PMID: 25398437, PMCID: PMC4286469, PII: 0008-5472.CAN-14-2405, DOI: 10.1158/0008-5472.CAN-14-2405, ISSN: 1538-7445.

Hockemeyer K, Janetopoulos C, Terekhov A, Hofmeister W, Vilgelm A, Costa L, Wikswo JP, Richmond A. Engineered three-dimensional microfluidic device for interrogating cell-cell interactions in the tumor microenvironment. Biomicrofluidics. 2014 Jul; 8(4): 44105. PMID: 25379090, PMCID: PMC4189212, PII: 1.4890330, PII: 006404BMF, DOI: 10.1063/1.4890330, ISSN: 1932-1058.

Davis TA, Vilgelm AE, Richmond A, Johnston JN. Preparation of (-)-Nutlin-3 using enantioselective organocatalysis at decagram scale. J. Org. Chem [print-electronic]. 2013 Nov 11/1/2013; 78(21): 10605-16. PMID: 24127627, PMCID: PMC3880828, DOI: 10.1021/jo401321a, ISSN: 1520-6904.

Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, Thu YM, Kantrow S, Splittgerber RC, Short S, Amiri KI, Ecsedy JA, Sosman JA, Kelley MC, Richmond A. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-¿B impairs this drug-induced senescence. EMBO Mol Med [print-electronic]. 2013 Jan; 5(1): 149-66. PMID: 23180582, PMCID: PMC3569660, DOI: 10.1002/emmm.201201378, ISSN: 1757-4684.

Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A. RAF265 inhibits the growth of advanced human melanoma tumors. Clin. Cancer Res [print-electronic]. 2012 Apr 4/15/2012; 18(8): 2184-98. PMID: 22351689, PMCID: PMC3724517, PII: 1078-0432.CCR-11-1122, DOI: 10.1158/1078-0432.CCR-11-1122, ISSN: 1078-0432.

Vilgelm AE, Zaika AI, Prasolov VS. [The coordinated interaction of multifunctional members of p53 family determines many key processes in multicellular organisms]. Mol. Biol. (Mosk.). 2011 Jan; 45(1): 180-97. PMID: 21485507, ISSN: 0026-8984.

Vilgelm AE, Hong SM, Washington MK, Wei J, Chen H, El-Rifai W, Zaika A. Characterization of ¿Np73 expression and regulation in gastric and esophageal tumors. Oncogene [print-electronic]. 2010 Oct 10/28/2010; 29(43): 5861-8. PMID: 20676143, PMCID: PMC4152004, PII: onc2010319, DOI: 10.1038/onc.2010.319, ISSN: 1476-5594.

Wei J, Nagy TA, Vilgelm A, Zaika E, Ogden SR, Romero-Gallo J, Piazuelo MB, Correa P, Washington MK, El-Rifai W, Peek RM, Zaika A. Regulation of p53 tumor suppressor by Helicobacter pylori in gastric epithelial cells. Gastroenterology [print-electronic]. 2010 Oct; 139(4): 1333-43. PMID: 20547161, PMCID: PMC2949494, PII: S0016-5085(10)00877-2, DOI: 10.1053/j.gastro.2010.06.018, ISSN: 1528-0012.

Vilgelm AE, Washington MK, Wei J, Chen H, Prassolov VS, Zaika AI. Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors. Mol. Cancer Ther [print-electronic]. 2010 Mar; 9(3): 693-705. PMID: 20197393, PMCID: PMC2838189, PII: 1535-7163.MCT-09-0912, DOI: 10.1158/1535-7163.MCT-09-0912, ISSN: 1538-8514.

Vilgelm A, El-Rifai W, Zaika A. Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist. Updat [print-electronic]. 2008 Aug; 11(4-5): 152-63. PMID: 18801697, PMCID: PMC2585826, PII: S1368-7646(08)00046-0, DOI: 10.1016/j.drup.2008.08.001, ISSN: 1532-2084.

Wei J, O'Brien D, Vilgelm A, Piazuelo MB, Correa P, Washington MK, El-Rifai W, Peek RM, Zaika A. Interaction of Helicobacter pylori with gastric epithelial cells is mediated by the p53 protein family. Gastroenterology [print-electronic]. 2008 May; 134(5): 1412-23. PMID: 18343378, PMCID: PMC2430883, PII: S0016-5085(08)00178-9, DOI: 10.1053/j.gastro.2008.01.072, ISSN: 1528-0012.

Vilgelm A, Wei JX, Piazuelo MB, Washington MK, Prassolov V, El-Rifai W, Zaika A. DeltaNp73alpha regulates MDR1 expression by inhibiting p53 function. Oncogene [print-electronic]. 2008 Apr 4/3/2008; 27(15): 2170-6. PMID: 17952118, PMCID: PMC4066670, PII: 1210862, DOI: 10.1038/sj.onc.1210862, ISSN: 1476-5594.

Tomkova K, El-Rifai W, Vilgelm A, Kelly MC, Wang TC, Zaika AI. The gastrin gene promoter is regulated by p73 isoforms in tumor cells. Oncogene [print-electronic]. 2006 Sep 9/28/2006; 25(44): 6032-6. PMID: 16636659, PII: 1209610, DOI: 10.1038/sj.onc.1209610, ISSN: 0950-9232.

Vilgelm A, Lian Z, Wang H, Beauparlant SL, Klein-Szanto A, Ellenson LH, Di Cristofano A. Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice. Cancer Res. 2006 Apr 4/1/2006; 66(7): 3375-80. PMID: 16585156, PII: 66/7/3375, DOI: 10.1158/0008-5472.CAN-05-4019, ISSN: 0008-5472.

Available Postdoctoral Position Details
Posted: 10/26/2018

A postdoctoral position to study tumor cell intrinsic mechanisms modulating anti-tumor immunity is available in the laboratory of Dr. Anna Vilgelm in the Department of Pharmacology at Vanderbilt University School of Medicine.

As a postdoctoral fellow in Dr. Vilgelm’s group you will have an opportunity to engage in high impact translational research of tumor immune microenvironment and immunotherapy response. The project will utilize clinically-relevant models such as patient-derived xenografts, humanized mice, patient-derived organoids that are established by our group. Competitive NIH scale pay plus benefits will be provided. Career development activities, including but not limited to attendance of local and national scientific meetings, committee service, student training, fellowship, travel and other award applications will be supported and encouraged.

The successful candidate will have or be close to obtaining PhD in a field related to cancer biology and/or immunology. Prior experience with mouse studies, immunofluorescent tissue staining, flow cytometry, CRISPR, and/or tumor and immune cell culture will be a plus. The position will require a focused, motivated and creative individual who is interested to contribute at least 2 years to postdoctoral training.

The laboratory of Dr. Vilgelm is supported by grants from NIH and private foundations. To apply send your CV including contact information of 3 references to